查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954347

癌症幹細胞市場分析及預測（至2035年）：按類型、產品類型、服務、技術、應用、最終用戶、流程、設備、解決方案分類

Cancer Stem Cells Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 300 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計癌症幹細胞市場規模將從2024年的39億美元成長到2034年的84億美元，複合年成長率約為7.3%。癌症幹細胞市場主要關注腫瘤內部存在的、具有自我更新能力並驅動癌症進展和轉移的細胞。該市場涵蓋靶向這些細胞的治療方法，旨在預防腫瘤復發並改善治療效果。生物技術的進步和癌症發病率的上升正在推動市場成長，凸顯了開發創新治療方法和個人化醫療方法來有效抑制癌症幹細胞的必要性。

受癌症研究和標靶治療進展的推動，癌症幹細胞市場預計將迎來顯著成長。以細分市場來看，治療領域表現最為突出，尤其是在單株抗體和小分子抑制劑方面。這些治療方法對於針對癌症幹細胞路徑至關重要，並已展現出令人矚目的治療效果。診斷領域也緊隨其後，生物標記識別和影像技術在早期檢測和個人化治療策略中發揮關鍵作用。基於細胞的檢測領域發展勢頭強勁，反映出體外檢測和藥物篩檢的需求日益成長。此外，將傳統療法與新型癌症幹細胞標靶療法結合的聯合治療的興起也值得關注。這一趨勢推動了市場向綜合治療方法的轉變。生物製藥公司與研究機構之間的研發投入和合作正在加速創新，並為這個不斷變化的環境中的相關人員帶來盈利的機會。

市場區隔
類型 細胞類型，腫瘤類型
產品 細胞株、設備、耗材和試劑盒
服務 細胞培養服務、生物銀行服務、冷凍保存
科技 細胞分離技術、細胞分析技術
應用領域 研究、臨床研究、轉化研究、藥物發現
最終用戶 生技公司、製藥公司、研究機構、醫院和診所
過程 體內、體外、體外
裝置 細胞分選裝置，流式細胞儀
解決方案 癌症幹細胞檢測、癌症幹細胞標記物

癌症幹細胞市場正經歷動態變化，市場佔有率因定價策略和創新產品的推出而波動。各公司一方面尋求透過具競爭力的價格來擴大市場佔有率，另一方面也透過新產品的推出來拓展治療選擇。市場格局的特點是研發投入激增，旨在提高治療效果和改善患者預後，這推動了市場顯著成長，越來越多的產品平臺等候核准。策略聯盟和合作進一步加速了市場發展勢頭，並為先進的癌症幹細胞療法鋪平了道路。在競爭基準方面，成熟企業正利用其豐富的產品系列來維持競爭優勢。新興企業則憑藉創新技術和策略聯盟進入市場。監管的影響至關重要，嚴格的指導方針影響產品開發和市場准入。北美和歐洲由於擁有有利的法規結構而處於領先地位，而亞太地區則在不斷成長的投資和政府扶持政策的推動下，正崛起為一個盈利的市場。競爭格局高度分散，研發的持續進步正在推動市場向前發展。市場參與企業正專注於策略性併購，以擴大其全球企業發展。

主要趨勢和促進因素：

癌症幹細胞市場正經歷變革性成長，這主要得益於癌症研究和個人化醫療的進步。一個關鍵趨勢是，人們越來越關注專門針對癌症幹細胞的標靶治療，這有望帶來更有效的治療效果。基因組學和蛋白​​質組學的技術進步為這一轉變提供了支持，這些技術進步使我們對癌症幹細胞的生物學特性有了更深入的了解。此外，全球癌症發生率的不斷上升也推動了市場需求。隨著癌症發病率的持續成長，人們越來越迫切地需要創新治療方法來提高存活率和生活品質。另一個促進因素是公共和私營部門對癌症研究投入的不斷增加，這正在促進新型治療方法的開發。此外，生物技術公司和學術機構之間的合作正在加速研究成果向臨床應用的轉化。這些夥伴關係對於克服藥物開發和監管核准的挑戰至關重要。市場也見證了旨在擴大產品系列和增強研發能力的策略聯盟和併購活動的增加。人們對癌症幹細胞的認知不斷加深，為企業開發突破性治療方法創造了眾多機會，這些療法將重新定義癌症治療模式。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 按細胞類型
    • 腫瘤類型
  • 市場規模及預測：依產品分類
    • 細胞株
    • 裝置
    • 消耗品
    • 成套工具
  • 市場規模及預測：依服務分類
    • 細胞培養服務
    • 生物銀行服務
    • 冷凍保存
  • 市場規模及預測：依技術分類
    • 細胞分離技術
    • 細胞分析技術
  • 市場規模及預測：依應用領域分類
    • 出於研究目的
    • 臨床應用
    • 轉化研究
    • 藥物發現
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 研究所
    • 醫院和診所
  • 市場規模及預測：依製程分類
    • In vivo
    • 體外
    • Ex Vivo
  • 市場規模及預測：依設備分類
    • 細胞分選裝置
    • 流式細胞儀
  • 市場規模及預測：按解決方案分類
    • 癌症幹細胞檢測
    • 癌症幹細胞標記物

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Stemline Therapeutics
  • Onco Med Pharmaceuticals
  • Verastem
  • Asterias Biotherapeutics
  • Stemcentrx
  • Oncolys Bio Pharma
  • Caladrius Biosciences
  • Cytori Therapeutics
  • Epicent Rx
  • Tiziana Life Sciences
  • Immuno Cellular Therapeutics
  • Oryzon Genomics
  • Bio Time
  • Epizyme
  • Karyopharm Therapeutics
  • Fortress Biotech
  • Neuralstem
  • Bio Eclipse Therapeutics
  • Agenus
  • Cellectar Biosciences

第9章：關於我們

簡介目錄
Product Code: GIS26484

Cancer Stem Cells Market is anticipated to expand from $3.9 billion in 2024 to $8.4 billion by 2034, growing at a CAGR of approximately 7.3%. The Cancer Stem Cells Market focuses on cells within tumors that possess the ability to self-renew and drive cancer progression and metastasis. This market encompasses therapies targeting these cells to prevent tumor recurrence and improve treatment efficacy. Advances in biotechnology and increasing cancer prevalence drive market growth, emphasizing the need for innovative treatments and personalized medicine approaches to effectively combat cancer stem cells.

The Cancer Stem Cells Market is poised for significant growth, driven by advancements in cancer research and targeted therapies. Among the segments, the therapeutics sub-segment emerges as a top performer, particularly in monoclonal antibodies and small molecule inhibitors. These therapies are pivotal in targeting cancer stem cell pathways, offering promising treatment outcomes. The diagnostics sub-segment follows closely, with biomarker identification and imaging technologies playing a crucial role in early detection and personalized treatment strategies. The cell-based assays segment is gaining momentum, reflecting the increasing demand for in vitro testing and drug screening. Furthermore, the rise of combination therapies, integrating traditional treatments with novel cancer stem cell-targeted approaches, is noteworthy. This trend underscores the market's shift towards comprehensive treatment regimens. Investments in R&D and collaborations between biopharmaceutical companies and research institutions are accelerating innovation, highlighting lucrative opportunities for stakeholders in this evolving landscape.

Market Segmentation
TypeCell Type, Tumor Type
ProductCell Lines, Instruments, Consumables, Kits
ServicesCell Culture Services, Biobanking Services, Cryopreservation
TechnologyCell Separation Technology, Cell Analysis Technology
ApplicationResearch Applications, Clinical Applications, Translational Research, Drug Discovery
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals and Clinics
ProcessIn Vivo, In Vitro, Ex Vivo
DeviceCell Sorters, Flow Cytometers
SolutionsCancer Stem Cell Assays, Cancer Stem Cell Markers

The Cancer Stem Cells Market is witnessing a dynamic shift, with market share being influenced by pricing strategies and innovative product launches. Companies are focusing on competitive pricing to capture a larger share, while new product launches are enhancing therapeutic options. The market landscape is characterized by a surge in research and development, aimed at improving treatment efficacy and patient outcomes. This has led to a robust pipeline of products awaiting regulatory approval, positioning the market for significant growth. The strategic alliances and collaborations are further driving market momentum, paving the way for advanced cancer stem cell therapies. In terms of competition benchmarking, established players are leveraging their extensive portfolios to maintain a competitive edge. Emerging companies are entering the market with novel technologies and strategic partnerships. Regulatory influences are pivotal, with stringent guidelines impacting product development and market entry. North America and Europe are at the forefront due to favorable regulatory frameworks, while Asia-Pacific is emerging as a lucrative market, driven by increasing investments and supportive government policies. The competitive landscape is highly fragmented, with continuous advancements in research propelling the market forward. Market participants are focusing on strategic mergers and acquisitions to expand their global footprint.

Geographical Overview:

The Cancer Stem Cells Market is witnessing dynamic growth across various regions, each presenting unique opportunities. North America leads, driven by advanced research facilities and substantial investments in biotechnology. The presence of major pharmaceutical companies further accelerates market expansion. Europe follows, with robust government support for cancer research and a strong focus on innovative therapies. The region's regulatory framework enhances market growth. In Asia Pacific, rapid economic development and increasing healthcare expenditure fuel market expansion. Countries like China and India are emerging as key players, investing heavily in cancer research. The growing prevalence of cancer in these regions also drives demand. Latin America and the Middle East & Africa are nascent markets with significant potential. In Latin America, improved healthcare infrastructure and rising awareness contribute to market growth. Meanwhile, the Middle East & Africa are recognizing the importance of investing in advanced cancer treatments to improve patient outcomes.

Global tariffs and geopolitical tensions are profoundly impacting the Cancer Stem Cells Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing their biopharmaceutical capabilities to mitigate reliance on imports, while China is accelerating its domestic R&D to counteract Western restrictions. Taiwan, though a key player in biotech, faces geopolitical vulnerabilities. The global parent market for cancer treatments is robust, driven by technological advancements and increasing cancer incidences. By 2035, the market is anticipated to witness substantial growth, contingent upon strategic alliances and innovation. Concurrently, Middle East conflicts are influencing global supply chains, potentially escalating energy prices and impacting manufacturing costs across these nations, necessitating strategic energy procurement and supply chain resilience.

Key Trends and Drivers:

The Cancer Stem Cells Market is experiencing transformative growth, driven by advancements in cancer research and personalized medicine. A key trend is the increasing focus on targeted therapies that specifically address cancer stem cells, promising more effective treatment outcomes. This shift is supported by technological advancements in genomics and proteomics, enabling deeper insights into cancer stem cell biology. Additionally, the rising prevalence of cancer globally is propelling market demand. As cancer incidence continues to climb, there is a heightened urgency for innovative treatments that can improve survival rates and quality of life. Another driver is the growing investment in cancer research by both public and private sectors, fueling the development of novel therapeutic approaches. Furthermore, collaborations between biotech companies and academic institutions are accelerating the translation of research findings into clinical applications. These partnerships are pivotal in overcoming the challenges associated with drug development and regulatory approvals. The market is also witnessing an increase in strategic alliances and mergers, aimed at expanding product portfolios and enhancing R&D capabilities. As the understanding of cancer stem cells evolves, opportunities abound for companies to develop groundbreaking therapies that could redefine cancer treatment paradigms.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cell Type
    • 4.1.2 Tumor Type
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Kits
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Culture Services
    • 4.3.2 Biobanking Services
    • 4.3.3 Cryopreservation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Separation Technology
    • 4.4.2 Cell Analysis Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Research Applications
    • 4.5.2 Clinical Applications
    • 4.5.3 Translational Research
    • 4.5.4 Drug Discovery
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals and Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo
    • 4.7.2 In Vitro
    • 4.7.3 Ex Vivo
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Cell Sorters
    • 4.8.2 Flow Cytometers
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Cancer Stem Cell Assays
    • 4.9.2 Cancer Stem Cell Markers

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Stemline Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Onco Med Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Verastem
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Asterias Biotherapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Stemcentrx
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Oncolys Bio Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Caladrius Biosciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cytori Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Epicent Rx
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tiziana Life Sciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immuno Cellular Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Oryzon Genomics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio Time
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Epizyme
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Karyopharm Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Fortress Biotech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Neuralstem
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bio Eclipse Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Agenus
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cellectar Biosciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us